BACKGROUND: Prompt detection of transplant-related complications (TRC) as infections, acute graft-versus-host disease (aGVHD), microangiopathic hemolytic anemia, or veno-occlusive disease following allogeneic hematopoietic stem cell transplantation (HSCT) is essential. PATIENTS AND METHODS: We conducted a prospective trial on clinical significance of C-reactive protein (CRP), interleukin-6 (IL-6) and procalcitonin (PCT) serum levels in TRC. A total of 350 stem cell recipients were admitted. CRP, IL-6 and PCT were analyzed prior to conditioning and weekly until 8 wk after HSCT. TRC were recorded weekly throughout the study. RESULTS: CRP (4.4 mg/dL vs. 12.8 mg/dL; P < 0.001), IL-6 (93 ng/mL vs. 1.138 ng/mL; P < 0.001) and PCT (0.8 ng/dL vs. 5.7 ng/dL; P < 0.001) were increased in infectious complications. Only PCT differentiated between infection and other TRC. Exclusive aGVHD did not increase CRP (4.4 mg/dL vs. 5.7 mg/dL; n.s.), IL-6 (93 ng/mL vs. 153 ng/mL; n.s.) and PCT (0.8 ng/dL vs. 0.8 ng/dL; n.s.). CRP (6.1 mg/dL vs. 3.1 mg/dL; P < 0.001) and IL-6 (295 ng/mL vs. 122 ng/mL; P = 0.001) were decreased during steroid therapy, but not PCT (2.3 ng/dL vs. 2.0 ng/dL; n.s.). CONCLUSION: Our study confirmed CRP, IL-6 and PCT serum levels as helpful markers for TRC. PCT can differentiate infection from GVHD despite steroid therapy. Further trials are needed focusing on the identification of patients who benefit from early risk stratification.
BACKGROUND: Prompt detection of transplant-related complications (TRC) as infections, acute graft-versus-host disease (aGVHD), microangiopathic hemolytic anemia, or veno-occlusive disease following allogeneic hematopoietic stem cell transplantation (HSCT) is essential. PATIENTS AND METHODS: We conducted a prospective trial on clinical significance of C-reactive protein (CRP), interleukin-6 (IL-6) and procalcitonin (PCT) serum levels in TRC. A total of 350 stem cell recipients were admitted. CRP, IL-6 and PCT were analyzed prior to conditioning and weekly until 8 wk after HSCT. TRC were recorded weekly throughout the study. RESULTS:CRP (4.4 mg/dL vs. 12.8 mg/dL; P < 0.001), IL-6 (93 ng/mL vs. 1.138 ng/mL; P < 0.001) and PCT (0.8 ng/dL vs. 5.7 ng/dL; P < 0.001) were increased in infectious complications. Only PCT differentiated between infection and other TRC. Exclusive aGVHD did not increase CRP (4.4 mg/dL vs. 5.7 mg/dL; n.s.), IL-6 (93 ng/mL vs. 153 ng/mL; n.s.) and PCT (0.8 ng/dL vs. 0.8 ng/dL; n.s.). CRP (6.1 mg/dL vs. 3.1 mg/dL; P < 0.001) and IL-6 (295 ng/mL vs. 122 ng/mL; P = 0.001) were decreased during steroid therapy, but not PCT (2.3 ng/dL vs. 2.0 ng/dL; n.s.). CONCLUSION: Our study confirmed CRP, IL-6 and PCT serum levels as helpful markers for TRC. PCT can differentiate infection from GVHD despite steroid therapy. Further trials are needed focusing on the identification of patients who benefit from early risk stratification.
Authors: K S R Massaro; R Macedo; B S de Castro; F Dulley; M S Oliveira; M A S Yasuda; A S Levin; S F Costa Journal: Infection Date: 2014-09-30 Impact factor: 3.553
Authors: Julianna V F Roddy; Bradley M Haverkos; Ali McBride; Kathryn M Leininger; Samantha Jaglowski; Sam Penza; Rebecca Klisovic; William Blum; Sumithira Vasu; Craig C Hofmeister; Don M Benson; Leslie A Andritsos; Steven M Devine; Yvonne A Efebera Journal: Leuk Lymphoma Date: 2015-07-03
Authors: S Weischendorff; K Kielsen; H Sengeløv; K Jordan; C H Nielsen; A E Pedersen; L P Ryder; A Juul; K G Müller Journal: Bone Marrow Transplant Date: 2017-04-24 Impact factor: 5.483
Authors: Xin Shelley Wang; Qiuling Shi; Lori A Williams; Charles S Cleeland; Gary M Mobley; James M Reuben; Bang-Ning Lee; Sergio A Giralt Journal: Cancer Date: 2008-10-15 Impact factor: 6.860
Authors: Andrew S Artz; Amittha Wickrema; Shira Dinner; Lucy A Godley; Masha Kocherginsky; Olatoyosi Odenike; Elizabeth S Rich; Wendy Stock; Jodie Ulaszek; Richard A Larson; Koen van Besien Journal: Biol Blood Marrow Transplant Date: 2008-11 Impact factor: 5.742
Authors: Hans Jürgen Dornbusch; Volker Strenger; Petra Sovinz; Herwig Lackner; Wolfgang Schwinger; Reinhold Kerbl; Christian Urban Journal: Support Care Cancer Date: 2008-01-15 Impact factor: 3.603